Connect your AI

Alumis Inc. ALMS Change in Other Assets

Change in Other Assets at other companies

AmgenAMGN

-$8M-104%

Oruka Therapeutics, Inc.ORKA

$60K—

Celldex TherapeuticsCLDX

-$6.28M-239%

Vera TherapeuticsVERA

$5.14M-12.5%

Dianthus TherapeuticsDNTH

$2.33M+21.9%

Protagonist TherapeuticsPTGX

$1.92M+102%

Other financials

Income statement

Revenue$1.7M-90.0%

Operating income-$98.4M+3.1%

Net income-$93.1M+6.0%

EPS (diluted)-$0.74+59.3%

Balance sheet

Cash & equivalents$63.9M-50.3%

Total debt$35.7M+1,881%

Total equity$567.0M+237%

Total assets$671.6M+157%

Cash flow

Operating cash flow-$87.1M-8.4%

CapEx$164.0K+343%

Free cash flow-$87.2M-8.5%

Valuation

Market cap$3.12B+739%

Enterprise value$3.1B+1,238%

P/S371.9×—

Profitability

Operating margin-5,364%—

Net margin-2,825.7%—

FCF margin-4,487.4%—

Returns & leverage

Return on equity-64.6%—

Debt / equity0.1×+0.1×

Current ratio7.5×+3.8×

Where this comes from

Reported directly by Alumis Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherNoncurrentAssets.

The official record: Alumis Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alumis Inc.'s change in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Alumis Inc.'s change in other assets?: Alumis Inc. (ALMS) reported change in other assets of $545K in Q1 2026.
How has Alumis Inc.'s change in other assets changed year-over-year?: Alumis Inc.'s change in other assets increased by 1334.2% year-over-year, from $38K to $545K.
What does change in other assets mean?: Change in miscellaneous assets affecting operating cash flow.